A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Peer Review reports

Original Submission
13 May 2014	Submitted	Original manuscript
13 May 2014	Author responded	Author comments - yun wang
Resubmission - Version 2
13 May 2014	Submitted	Manuscript version 2
15 May 2014	Author responded	Author comments - yun wang
Resubmission - Version 3
15 May 2014	Submitted	Manuscript version 3
26 Jul 2014	Reviewed	Reviewer Report - Andrew Clamp
3 Aug 2014	Reviewed	Reviewer Report - Alain Zeimet
15 Oct 2014	Author responded	Author comments - yun wang
Resubmission - Version 4
15 Oct 2014	Submitted	Manuscript version 4
17 Nov 2014	Author responded	Author comments - yun wang
Resubmission - Version 5
17 Nov 2014	Submitted	Manuscript version 5
Publishing
20 Nov 2014	Editorially accepted
11 Dec 2014	Article published	10.1186/1471-2407-14-937

Back to article page